High-dose Chemotherapy Followed by Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Follicular Non-Hodgkin's Lymphoma in the Rituximab Era
Restricted accessResearch articleFirst published online January, 2015
High-dose Chemotherapy Followed by Autologous and Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Follicular Non-Hodgkin's Lymphoma in the Rituximab Era
High-dose chemotherapy in lymphomas, and mainly non-Hodgkin's lymphomas, has been advancing since the 1970s. This therapeutic strategy is based on the supposed existence of a dose-response curve for cytotoxic agents. However, the available data are contradictory, so high-dose chemotherapy cannot be guaranteed as consolidation treatment for first-remission follicular lymphoma or diffuse large cell lymphoma. The objective of this paper is to review the current knowledge about high-dose chemotherapy followed by hematopoietic stem cell transplantation in follicular non-Hodgkin's lymphoma. The published studies on follicular lymphoma after first remission, recurrent follicular lymphoma, and transformed follicular lymphoma were assessed together with the data available on diffuse large cell lymphoma. During analysis of the studies, difficulties were encountered in comparing studies due to the heterogeneous nature of the data. High-dose chemotherapy as consolidation treatment after first remission or in recurrent or refractory disease was also analyzed.
HorningS.J., RosenbergS.A.The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med.1984; 311(23): 1471–1475.
3.
ApostolidisJ., ForanJ.M., JohnsonP.W.. Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol.1999; 17(1): 216–221.
4.
González-BarcaE., Fernández de SevillaA., Domingo-ClarosA.. Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival. Bone Marrow Transplant.2000; 26(10): 1051–1056.
5.
VosoM.T., MartinS., HohausS.. Prognostic factors for the clinical outcome of patients with follicular lymphoma following high-dose therapy and peripheral blood stem cell transplantation (PBSCT). Bone Marrow Transplant.2000; 25(9): 957–964.
6.
HorningS.J., NegrinR.S., HoppeR.T.. High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood.2001; 97(2): 404–409.
7.
ColombatP., CornilletP., DeconinckE.. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study. Bone Marrow Transplant.2000; 26(9): 971–977.
8.
MontotoS., CanalsC., RohatinerA.Z.; EBMT Lymphoma Working Party. Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia.2007; 21(11): 2324–2331.
9.
LenzG., DreylingM., SchiegnitzE.; German Low-Grade Lymphoma Study Group. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood.2004; 104(9): 2667–2674.
10.
GyanE., FoussardC., BertrandP.. Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang (GOELAMS). High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELMANS with final results after a median follow-up of 9 years. Blood.2009; 113: 995–1001.
11.
LenzG., DreylingM., SchiegnitzE.. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol.2004; 22(24): 4926–4933.
12.
SebbanC., MounierN., BrousseN.. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood.2006; 108(8): 2540–2544.
13.
LadettoM., De MarcoF., BenedettiF.; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL). Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood.2008; 111(8): 4004–4013.
14.
Al KhaboriM., de AlmeidaJ.R., GuyattG.H., KuruvillaJ., CrumpM.Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst.2012; 104(1): 18–28.
15.
SchaafM., ReiserM., BorchmannP., EngertA., SkoetzN.High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database Syst Rev.2012; 1: CD007678.
16.
MorschhauserF., RadfordJ., Van HoofA.. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol.2008; 26(32): 5156–5164.
17.
SallesG., SeymourJ.F., OffnerF.. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet.2011; 377(9759): 42–51.
18.
KhalB.S., HongF., WilliamsM.E.. Results of Eastern Cooperative Oncology Group protocol E4402 (RESORT): a randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. Blood (ASH Annual Meeting Abstracts)2011; 118(21): LBA6.
DreylingM., GhielminiM., MarcusR., SallesG., VitoloU.; ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2011; 22(Suppl 6): vi59–vi63.
21.
GopalA.K., GuthrieK.A., RajendranJ.. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood.2011; 118(4): 1132–1139.
VoseJ.M., BiermanP.J., LoberizaF.R.. Long-term outcomes of autologous stem cell transplantation for follicular non-Hodgkin lymphoma: effect of histological grade and Follicular International Prognostic Index. Biol Blood Marrow Transplant.2008; 14(1): 36–42.
24.
RohatinerA.Z., NadlerL., DaviesA.J.. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol.2007; 25(18): 2554–2559.
25.
SchoutenH.C., QianW., KvaloyS.. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol.2003; 21(21): 3918–3927.
26.
BrownJ.R., FengY., GribbenJ.G.. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. Biol Blood Marrow Transplant.2007; 13(9): 1057–1065.
27.
KornackerM., StummJ., PottC.. Characteristics of relapse after autologous stem-cell transplantation for follicular lymphoma: a long-term follow-up. Ann Oncol.2009; 20(4): 722–728.
28.
Le GouillS., De GuibertS., PlancheL.; GELA and GOELAMS. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study. Haematologica.2011; 96(8): 1128–1135.
29.
KeeneyG.E., GooleyT.A., PhamR.N.. The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Leuk Lymphoma.2007; 48(10): 1961–1967.
30.
PhamR.N., GooleyT.A., KeeneyG.E.. The impact of histologic grade on the outcome of high-dose therapy and autologous stem cell transplantation for follicular lymphoma. Bone Marrow Transplant.2007; 40(11): 1039–1044.
31.
MontotoS., CorradiniP., DreylingM.. Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party. Haematologica.2013; 98(7): 1014–1021.
32.
FreedmanA.S., NeubergD., MauchP.. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood.1999; 94(10): 3325–3333.
33.
TarellaC., CorradiniP., AstolfiM.. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia.1999; 13(9): 1456–1462.
34.
TarellaC., ZanniM., MagniM.. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey. J Clin Oncol.2008; 26(19): 3166–3175.
35.
ArcainiL., MontanariF., AlessandrinoE.P.. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Ann Oncol.2008; 19(7): 1331–1335.
HicksL.K., WoodsA., BucksteinR.. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma. Bone Marrow Transplant.2009; 43(9): 701–708.
38.
MahéB., MilpiedN., MellerinM.P.. PCR detection of residual Bcl-2/IgH-positive cells after high-dose therapy with autologous stem cell transplantation is a prognostic factor for event-free survival in patients with low-grade follicular non-Hodgkin's lymphoma. Bone Marrow Transplant.2003; 31(6): 467–473.
39.
FinkeJ.The role of stem cell transplantation in the treatment of follicular lymphoma. Semin Cancer Biol.2003; 13(3): 233–239.
40.
BruggerW., HirschJ., GrünebachF.. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol.2004; 15(11): 1691–1698.
41.
PettengellR., SchmitzN., GisselbrechtC.; European Group for Blood and Marrow Transplantation. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract]. J Clin Oncol.2010; 28(15s): abstr 8005.
42.
ArmandP., KimH.T., HoV.T.. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant.2008; 14(4): 418–425.
43.
MandigersC.M., VerdonckL.F., MeijerinkJ.P., DekkerA.W., SchattenbergA.V., RaemaekersJ.M.Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation. Bone Marrow Transplant.2003; 32(12): 1159–1163.
44.
van BesienK.W., de LimaM., GiraltS.A.. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect. Bone Marrow Transplant.1997; 19(10): 977–982.
45.
BloorA.J., ThomsonK., ChowdhryN.. High response rate to donor lymphocyte infusion after allogeneic stem cell transplantation for indolent non-Hodgkin lymphoma. Biol Blood Marrow Transplant.2008; 14(1): 50–58.
46.
van BesienK., LoberizaF.R.Jr., BajorunaiteR.. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood.2003; 102(10): 3521–3529.
47.
PeniketA.J., Ruiz de ElviraM.C., TaghipourG.. European Bone Marrow Transplantation (EBMT) Lymphoma Registry. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant.2003; 31(8): 667–678.
48.
TozeC.L., BarnettM.J., ConnorsJ.M.. Long-term disease-free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation. Br J Haematol.2004; 127(3): 311–321.
HosingC., SalibaR.M., McLaughlinP.. Long-term results favor allogeneic over autologous hematopoietic stem cell transplantation in patients with refractory or recurrent indolent non-Hodgkin's lymphoma. Ann Oncol.2003; 14(5): 737–744.
51.
KhouriI.F., SalibaR.M., ErwinW.D.. Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results. Blood.2012; 119(26): 6373–6378.
52.
SheaT., JohnsonJ., WesterveltP.; Cancer and Leukemia Group B. Reduced-intensity allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies: CALGB 109901. Biol Blood Marrow Transplant.2011; 17(9): 1395–1403.
53.
ThomsonK.J., MorrisE.C., MilliganD.. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol.2010; 28(23): 3695–3700.
54.
PiñanaJ.L., MartinoR., GayosoJ.; GELTAMO Group. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials. Haematologica.2010; 95(7): 1176–1182.
Kharfan-DabajaM.A., CutlerC.S.Rituximab for prevention and treatment of graft-versus-host disease. Int J Hematol.2011; 93(5): 578–585.
57.
CohenS., KissT., LachanceS.. Tandem autologous-allogeneic nonmyeloablative sibling transplantation in relapsed follicular lymphoma leads to impressive progression-free survival with minimal toxicity. Biol Blood Marrow Transplant.2012; 18(6): 951–957.
58.
KhouriI.F., McLaughlinP., SalibaR.M.. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood.2008; 111(12): 5530–5536.
59.
FriedbergJ.W., NeubergD., GribbenJ.G.. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant.1999; 5(4): 262–268.
60.
WilliamsC.D., HarrisonC.N., ListerT.A.; European Bone Marrow Transplant Lymphoma Working Party. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. J Clin Oncol.2001; 19(3): 727–735.
